posted
I remember when this was trading in the pennys a couple of yeasr ago. This is all time record volume something may be up with it. I bought some at .0007 and sitting bid with large order at .0006
"On November 30, 2006, the Chungs assigned the rights and interest in their Tubercin patent to a private Korean company, Hyolim Bio Co., Ltd. The Chungs are actively involved with Hyolim Bio Co., Ltd.
In February 2007, the Chungs notified the Securities and Exchange Commission (“SEC”) that their license agreement with Shinn Capital Group, Inc. had been terminated and that Hyolim Bio Co., Ltd. and the Chungs have no association in any manner with Ronald Shinn, Shinn Capital Group, Inc. or ArTec Inc. (“ATKJ”) and its website claims.
HTTD has a judgment against Ronald Shinn of approximately $210,000 based on the U.S. Court of Appeals ruling that Shinn is personally liable for breach of fiduciary duty to HTTD for damages on the basis of his misappropriation of corporate funds from HTTD.
HTTD has supplied all supporting documentation to the SEC regarding the securities fraud and other fraudulent activities committed by the prior officers and directors of the Company."
IP: Logged |
posted
Hard To Treat Diseases (HTDS) Pending Merger Update
Friday , January 02, 2009 07:00ET
CLEARWATER, FL, Jan. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's news release of December 30, 2008 where amongst other things the company addressed the targeted merger candidate, firstly the company is pleased to announce that it has appointed its new Chief Science Consultant.
The director of research and business development for the company is Andrea Zecevic Rubio. Andrea is a University of Toronto graduate specializing in the field of Microbiology. Andrea has worked for Pasteur Meriuex Connaught Laboratories (Now Aventis) for several years as a microbiologist, before starting her own consulting business in the field of medical research, and software developments in non medical fields. Andrea is fluent in several languages, such as Spanish, Italian, Portuguese, and English which the company will draw upon with International clients.
Andrea's mandate with HTDS is to research target merger companies in the medical sector that have great potential in bringing valuable products that can make a difference into the market and merging them with HTDS. In addition, Andrea's tasks will include consulting the HTDS management and board directors on the validity of medical operations in the capacity of scientific areas only.
Andrea has identified a suitable merger operating candidate. The merger candidate is a China based bio chemical company.
Andrea said "Currently we have sent two company representatives to examine a company in China that is currently the leading and the largest manufacturer and exporter of vaccines in China offering Hepatitis A Vaccine, Rabies Virus Vaccine, Influenza Virus Vaccine, Polio Vaccine, along with some pharmaceutical raw materials.
In addition, we have entered into a contract with several European companies that are currently at various stages of product launching, from a successful clinical trials stage, to a ready to launch product stage.
The European companies we have examined are currently focused on the chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis) SARS, Hepatitis C, HIV through the enhancement of already approved drugs such as "Virazole" and Tiazofurin.
We also have serious interest in a product that utilizes a natural human body defense from foreign substances as microorganisms, tumors, and antigenes. Beside antiviral effects, the product plays an important role in the battle against various tumors and diabetes."
For scientific dialogue and inquiry only Andrea can be reached via e mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com.
In other corporate updates, the company has completed a filing on Pink Sheets re China Medical company. This is a scrubbed version (relevant merger company named removed) until the transaction is closed. The company will post the East European merger candidate shortly.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
-------------------- " Cash is King "
IP: Logged |
posted
Nice volume increase on Friday. At .001 with a profile by O T C R E P O R T E R . C O M who has been hot lately with their " Morning Alerts ". Could move Monday morning .... jmho
-------------------- " Cash is King "
IP: Logged |
posted
Hard To Treat Diseases (HTDS) Completes E Europe Merger
Monday , January 05, 2009 07:30ET
CLEARWATER, FL, Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's various merger updates where amongst other things the company addressed several targeted merger candidates, the company is pleased to announce that it has finalized its bilateral negotiations with Slavica Bio Chem, www.slavicabiochem.com (Slavica).
Slavica Bio Chem is a spin off of Renuyu Biochem, a USA and a UK company, founded by Andrea Zecevic. Andrea currently acts as a head scientific advisor to HTDS. The company research and development dates back to 2005. The institute and the physical plant is located in Belgrade Serbia. The company has been completely self funding with private resources since its inception. Over the next several weeks Slavica management and its officers intend to provide a series of filings and updates on the company's efforts and progress in this field.
Under the agreement the medical team will receive payment in stock and options on HTDS security on a delivery and performance based schedule. Consideration for Slavica is 300 million non-dilatable restricted shares to be distributed amongst all doctors involved in Belgrade Serbia research. Andrea Zecevic, as a vote of confidence in Slavica and who spearheaded the transaction, shall receive no stock in this transaction and in lieu will take stock options at a .03c strike price for up to 9% of the company common stock.
In other corporate news, the company representatives intend to visit mainland China for a second merger company discussions with a China based company in a similar field and research as Slavica with a significant operations already in place in China. Upon completion of the China merger, the company intends to name its new CEO, officers and directors consisting primarily of medical professionals and business consultants.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
CONTACT: For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
For scientific dialogue and inquiry only contact Andrea Rubio Zecevic via e-mail at azconsulting2001*gmail.com. For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
-------------------- " Cash is King "
IP: Logged |
posted
Hard To Treat Diseases (HTDS) in Merger Talks with Mellow Hope, China
Wednesday, January 14, 2009 08:22ET
SHENZHEN, China, Jan. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com management representatives are currently in China negotiating a merger agreement with Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope).
Mellow Hope is the biggest exporter of Biological Vaccines in China, and has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestatin.
Mellow Hope revenues are currently in excess of $15 million USD, and growing.
Interim company CEO Keith Roberts noted "We think there are going to be strong synergies between our European division and Mellow Hope. Mellow Hope brings a substantial pharmaceutical production and testing capability to the forefront of the Company. In turn, HTDS can provide vital and meaningful assistance to Mellow Hope in developing its export business to Europe and beyond".
Based on initial negotiations, the company anticipates having a formal Letter of Intent in place within a week to ten days, and will provide additional updates on developments as they unfold.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001*gmail.com; For any corporate matters the readers should contact the company directly at corporate*htdsmedical.com
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
